Across hundreds of evaluations as an ADHD psychiatrist for women in Austin, I see the same biography repeat. Honor-roll student. Competent professional. Privately, a lifetime of compensating: lists for the lists, deadline adrenaline as a productivity system, a mind running six tracks at once, and an exhaustion no one can see because the output looks fine.
Then something breaks the compensation. A promotion, a child, perimenopause, or simply the cumulative cost. She finally gets evaluated. The diagnosis is ADHD. She is thirty-eight. Her first question is always the same: why didn’t anyone catch this?
The answer is structural, and it’s worth understanding precisely, because it’s the same reason her bloodwork has been called “normal” for years while she got steadily worse. As an ADHD psychiatrist for women in Austin, I often explain that ADHD in women frequently presents differently than the traditional textbook descriptions, leading many women to remain undiagnosed for decades.
Why the diagnosis is missed in women
ADHD was characterized through studies of hyperactive boys. The diagnostic template (disruptive, externalizing, visible) was built from that sample. Girls with ADHD more often present the inattentive type: internally restless rather than externally disruptive, daydreaming rather than disrupting, anxious rather than defiant. Teachers don’t refer quiet girls. The research literature now documents this under-recognition explicitly, along with its cost: later diagnosis, more accumulated comorbidity, more functional impairment by the time anyone looks (Skoglund et al.; Hinshaw’s longitudinal cohorts).
Two more mechanisms keep the diagnosis hidden in high-functioning women:
Intelligence masks it. A strong cognitive engine can brute-force its way through structure problems for decades. The deficit doesn’t disappear; it gets paid for privately, in time, sleep, and anxiety.
The comorbidity gets diagnosed instead. Anxiety and depression are downstream consequences of decades of unexplained struggle, and they are what most clinicians see first. Many women carry an anxiety diagnosis for fifteen years before anyone asks what the anxiety is managing. Treating the anxiety without mapping the attention system underneath is treating the alarm and ignoring the fire.
"Normal" is not the same as "optimized"
This is where my approach departs from most ADHD care, and it is the part that matters most for women.
When a woman is told her labs are “normal,” what that usually means is that she is not sick by the standard reference range. But reference ranges describe a broad population and were, for much of the foundational research, derived from data that underrepresented women, the same blind spot that runs through most of medicine’s history with female physiology. A single wide range answers one question: are you below the floor where disease is obvious? It does not answer the question her symptoms are actually asking: is this system adequately supplied for how my brain and my hormones actually work?
Iron is the clearest example, and it is central to ADHD specifically.
Iron is the rate-limiting cofactor for tyrosine hydroxylase, the enzyme that builds dopamine, the exact neurotransmitter ADHD medication acts on. The lab’s ferritin range is built to catch anemia. Its floor is a hematology threshold, the point below which red-cell production suffers. But the brain’s requirement for dopamine synthesis is not the same as the blood’s requirement for red cells. A woman can sit comfortably “in range” on her ferritin while her dopamine-producing machinery is quietly under-resourced. She is told her iron is fine because she isn’t anemic, while the system that makes her focus is running on a thin supply.
That is not a normal-range problem. It is an optimization problem, and the range was never designed to find it.
Why it surfaces in perimenopause and menopause
Here is the part that makes this a women’s story rather than a general one.
Estradiol supports dopamine signaling. As long as a woman’s estrogen is robust, it partially covers for a marginal supply underneath, including iron that is technically in range but functionally thin. The system gets by because hormones are buffering it.
Then the buffer thins. In the late luteal phase each month, postpartum, and most consequentially across perimenopause and into menopause, estradiol declines and fluctuates, and the support it was lending the dopamine system withdraws. Now the under-optimized iron, the marginal B12, the strained methylation that were getting away with it for years stop getting away with it. The woman who “suddenly can’t function” in her forties, who privately fears early dementia, is usually not developing dementia. Her hormonal buffer is receding at the same moment her underlying supply was never optimized in the first place. Two supports fail together, and the ADHD that was compensated for thirty years decompensates in eighteen months.
“Your labs are normal” is, to this woman, both technically true and completely useless. The whole point of my evaluation is to read her physiology against her hormonal stage, not against a population floor.
How I actually treat it
Medication does real work in ADHD, and I prescribe it. But a stimulant redistributes the dopamine a brain can make. It does not supply the raw materials, reduce the inflammation, or account for the hormonal stage the brain is operating in. Most psychiatry asks what dose. I ask what is this brain actually working with before and while I adjust the medication. Three systems, treated as inputs to the same dopamine machinery:
- Iron and the synthesis cofactors, optimized rather than merely in-range. I work up ferritin and read it against a functional target for cognition and a woman’s hormonal stage, not against the anemia floor. Where it’s low for her, correcting it can meaningfully change both symptoms and medication response. This single step is the most evidence-supported biological lever in ADHD, and it is the one most often skipped.
- Methylation and neurotransmitter supply. Folate, B12, and the methylation cycle feed the production of dopamine and norepinephrine. A meaningful share of people carry variants (such as in MTHFR) that reduce conversion of folate to its active form, L-methylfolate, which has trial support as an adjunct in depression and a plausible role wherever monoamine synthesis is taxed. I assess whether the machinery for making the neurotransmitters is adequately supplied before I keep adjusting the drug that moves them around. This is mechanism, not magic, and I frame it that way.
- Inflammation and the gut-brain axis, as a system input. Most of the body’s serotonin is produced in the gut, and the microbiome participates in neurotransmitter metabolism, nutrient absorption, and inflammatory tone, all of which affect brain function. I am deliberately careful here: this is a contributing input to optimize, not a cure to oversell. Improving absorption and lowering inflammatory load supports the terrain the medication operates on. It does not replace the medication, and I won’t pretend it does.
Then the medication, prescribed precisely and managed with the cycle and the hormonal stage in view. The reason this approach holds when a standard stimulant-only plan plateaus is simple: I am optimizing the terrain the medication works on, not just turning the dose up against a depleted system.
What a real evaluation involves
A twenty-minute screener and a same-day prescription is not an evaluation. Adult ADHD in women is a differential-diagnosis problem layered on a biological one. My assessment includes:
- Developmental and collateral history. The symptoms must trace back, even if the impairment was hidden by compensation.
- Differential mapping against anxiety disorders, depression, PMDD, bipolar II, thyroid disease, sleep apnea, and iron deficiency. Each can mimic or amplify attentional symptoms, and several routinely co-occur.
- Hormonal context. Cycle patterning, reproductive stage, and where relevant, coordinating treatment with that reality.
- Biological screening, read for optimization. Ferritin, B12 and folate, thyroid function, vitamin D, inflammatory and metabolic markers, sleep quality, interpreted against your physiology and hormonal stage rather than waved through because they clear the floor.
- Treatment architecture. Medication where indicated, with cycle-aware management; the supply and inflammation work above; structural and behavioral design; and treatment of comorbid conditions in the correct order. Sequence is strategy.
Who this is for
If you’ve been told your labs are “fine” while you slowly lost function, if you’ve read the research yourself and arrived with questions rather than just symptoms, if you want your decades of compensation understood as data rather than dismissed as “but you’re successful”: I built this evaluation for you.
If you’re looking for the fastest possible prescription, there are higher-volume settings for that, and you deserve a setting that matches your goal. I maintain a small roster so each evaluation can be this thorough. That’s by design.
The practice
Dr. Lauren Williams is a board-certified psychiatrist in Austin, Texas. As an ADHD psychiatrist for women in Austin, she frequently evaluates adult ADHD, particularly the late-diagnosed, high-functioning, hormonally layered presentation commonly seen in professional women. Care is structured around a comprehensive psychiatric and biological assessment; brief medication management is not the model.
If your experiences reflect the patterns described in this article, you may request a consultation. We’ll both find out if it’s a fit.
Frequently Asked Questions
Why are so many women diagnosed with ADHD as adults?
Diagnostic criteria were built from hyperactive boys. Women more often have the inattentive presentation, mask it with intelligence and effort, and get diagnosed with the downstream anxiety or depression instead. The ADHD surfaces when life load exceeds compensation, often in the 30s and 40s, frequently as hormones begin to shift.
Can "normal" iron labs still cause ADHD symptoms?
Yes. Iron is the rate-limiting cofactor for dopamine synthesis, and the lab ferritin range is built to detect anemia, not to reflect what the brain needs. A woman can be “in range” yet functionally under-supplied for dopamine production. This is an optimization question the standard reference range was not designed to answer.
Why did my ADHD get so much worse in perimenopause?
Estradiol supports dopamine signaling and partially buffers a marginal nutrient supply. As estrogen declines and fluctuates in perimenopause and menopause, that buffer thins, and an underlying supply that was “getting by” no longer is. ADHD that was compensated for decades can decompensate within a year or two.
Do hormones affect ADHD symptoms?
Yes. Estradiol modulates dopamine signaling. Many women experience symptom worsening and reduced medication response premenstrually, postpartum, and in perimenopause. Women with ADHD also carry a three- to four-fold elevated PMDD risk.
Can you have ADHD if you did well in school?
Yes. Academic success reflects compensation, not absence of the condition. Adult diagnosis requires evidence of long-standing symptoms and impairment, including the hidden cost of compensating.
Where can women get evaluated for ADHD in Austin?
Dr. Lauren Williams provides comprehensive adult ADHD evaluation for women in Austin, Texas, including iron and nutrient optimization, hormonal context, full differential diagnosis, and biological screening, in a private-pay specialty model.
